The formation of a natural black pearl is extremely rare - just like these pearls, the recipients of the EURORDIS Black...
Read more
A once-in-a-generation opportunity to optimise regulatory timelines to improve time to patient access
Only 58% of FDA-licensed therapies reach Europe in a comparable timeline. But for patients, every day counts. This report looks into the 67-day process from the final opinion of the Committee for Medicinal Products for Human Use (CHMP) to the final decision of the European Commission and recommends three solutions to improve patient access.
Overcrowded hospitals, delayed treatment and missed diagnoses put the most sick at greater risk.
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.